Read more

July 06, 2023
1 min read
Save

Treatment, dietary updates from the American Diabetes Association Scientific Sessions

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

At this year’s American Diabetes Association Scientific Sessions, held from June 23-26, health care providers from more than 115 countries gathered to learn about the latest research on diabetes care.

There were more than 200 sessions and 1,400 posters featuring data on prevention, diagnosis and management, including optimal dietary patterns and emerging treatment options.

Meeting mic_Adobe_224451506
This year’s American Diabetes Association Scientific Sessions included more than 200 sessions and 1,400 posters featuring data on optimal dietary patterns and emerging treatment options. Image: Adobe Stock

During one presentation, researchers reported findings that showed bempedoic acid significantly reduced the risk for major adverse cardiovascular events in high-risk primary prevention patients compared with placebo. The drug was also well-tolerated by those who were unable or unwilling to take statins.

Other research teams presented new data on drugs such as Mounjaro (tirzepatide, Eli Lilly) Rybelsus (semaglutide, Novo Nordisk) and retatrutide (Eli Lilly) that reduced weight in patients with obesity, and two experts debated whether early or late time-restricted eating confers more benefits.

Read these and more highlights from the conference below:

‘Simply stunning’: Bempedoic acid may cut CVD risk for primary prevention patients by 30%

In adults with elevated cardiovascular risk but without a prior clinical event and deemed statin intolerant, bempedoic acid reduced risk for major adverse cardiovascular events by 30% compared with placebo, researchers reported. Read more.

SURMOUNT-2: Tirzepatide confers about 15% weight loss in adults with obesity and diabetes.

Adults with obesity and type 2 diabetes achieved a 14.7% weight loss at 72 weeks with 15 mg tirzepatide, according to data from the SURMOUNT-2 trial. Read more.

‘This raises the bar’: Phase 2 data show 24% weight loss with triple-agonist retatrutide

Adults with obesity who received the highest dose of a once-weekly injection of retatrutide lost an average of 24.2% of their body weight at 48 weeks compared with placebo, data from a phase 2 study show. Read more.

Experts debate whether early or late time-restricted eating confers more benefits

Early time-restricted eating may confer more cardiometabolic benefits for adults than late time-restricted eating, but a later eating window may result in better adherence, according to two speakers. Read more.

Higher-dose oral semaglutide may be beneficial option for type 2 diabetes, obesity

Oral semaglutide 50 mg induces more than 15% weight loss in adults with obesity at 68 weeks and can reduce HbA1c by 2 percentage points at 52 weeks for those with type 2 diabetes, according to data from two phase 3 trials. Read more.